Ignite Creation Date:
2024-05-05 @ 4:58 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00357903
Status:
COMPLETED
Last Update Posted:
2017-02-09
First Post:
2006-07-26
Brief Title:
Open-Label Extension Treatment With Etanercept TNFRFc for Participating Patients in Etanercept TNFRFc Clinical Trials
Sponsor:
Amgen
Organization:
Amgen
Study Overview
Official Title:
Open-Label Extension Treatment With Tumor Necrosis Factor Receptor Fusion Protein TNFRFc for Participating Patients in Tumor Necrosis Factor Receptor Fusion Protein TNFRFc Clinical Trials
Status:
COMPLETED
Status Verified Date:
2017-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study was designed to provide all adult and pediatric arthritis patients placebo and etanerceptTNFRFc treated who have participated in clinical trials with etanercept TNFRFc the opportunity to receive continued treatment with etanercept TNFRFc The primary objective of this study is to examine safety parameters
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 160018 | None | None | None |